Ehave (Ticker: EHVVF) is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. Ehave’s mental health informatics platform facilitates make objective, data-driven decision making while keeping patients informed and engaged throughout their mental healthcare journey. Ehave offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf.
We Believe that a Game-Changing Technology is Long Overdue
Patients and their caregivers are often hindered by an outdated and inefficient mental healthcare delivery system – despite rapid innovation in other sectors, many practitioners rely upon diagnostic and treatment methodologies developed in the last century. We believe the mental health community is long overdue for a technology breakthrough to catapult patient care into the current era of data-driven decision making and personalized treatment.
Introducing the Ehave Platform
Ehave is proud to offer a mental health informatics platform that efficiently captures, integrates, and delivers high-quality, objective patient data. By bridging the substantial information gap in mental healthcare, while at the same time facilitating the deployment of diagnostic and treatment tools, we believe that we will empower mental healthcare providers and improve patient care.
An Evidence-Based Approach to Treatment Using Cannabis
The medical cannabis industry lacks comprehensive data for clinicians to draw from when advising patients on treatment plans, as well as reliable systems to track use and outcomes. Ehave is pioneering an evidence-based approach to treatment using cannabis, to improve the lives of patients and to support the emerging industry.
in partnership with
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (“ADHD”) is a common childhood disorder characterized by developmentally inappropriate levels of hyperactivity, impulsivity, and inattention. Despite extensive advances in understanding this complex disorder, improved methods for diagnosis and treatment are desired.
in partnership with
Ehave Solutions Benefit Users in a Variety of Industries
Ehave seeks to provide a turnkey set of solutions for mental healthcare clinicians, patients, pharmaceutical companies, researchers, and others who can benefit from objective data-driven insights. We believe the broad applicability of the Ehave Platform and the unmet need in mental healthcare positions Ehave for rapid expansion across multiple market segments.